Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy
Anneloes L. Noordhof, Ronald Damhuis, Lizza Hendriks, Adrianus J. de Langen, Wim Timens, Ben J.W. Venmans, Wouter H. van Geffen
Topics & Concepts
PembrolizumabKRASMedicineInternal medicineHazard ratioOncologyAdenocarcinomaPopulationLung cancerStage (stratigraphy)Retrospective cohort studyCancerColorectal cancerImmunotherapyConfidence intervalPaleontologyEnvironmental healthBiologyLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment